Advertisement
Research paper| Volume 42, ISSUE 2-3, P245-249, April 1982

Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia

DOI:https://doi.org/10.1016/0021-9150(82)90154-X
Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia
Previous ArticleDose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia
Next ArticleRate of LCAT-mediated cholesterol esterification and serum lipids during etiroxate therapy in hyperlipoproteinemia
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      As compared to normolipoproteinemic controls 10 male subjects with primary type IV hyperlipoproteinemia had higher apolipoprotein E and lower apolipoprotein C-II concentrations in the very low density lipoprotein (VLDL) fraction. After 8 weeks of treatment with 0.6. g/day bezafibrate, cholesterol and triglyceride in the serum and VLDL were significantly lower. The decrease of VLDL lipids was accompanied by a significant decrease of the apolipoproteins and of the lipid/protein ratio in VLDL. The analysis of the soluble VLDL apolipoproteins revealed a decrease of apo E and an increase of apo C1 and apo C2, resulting in a decrease of the apo E/apo C ratio.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Olsson A.G.
        • Rössner S.
        • Walldius G.
        • Carlson L.A.
        • Lang P.D.
        Effect of BM-15075 on lipoprotein concentrations in different types of hyperlipoproteinemia.
        Atherosclerosis. 1977; 27: 279
        • Weisweiler P.
        • Schwandt P.
        Lipoprotein lipids and apolipoproteins after six months' treatment with bezafibrate.
        Artery. 1980; 5: 402
        • Schwandt P.
        • Weisweiler P.
        Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
        Artery. 1980; 7: 464
        • Klose G.
        • Behrendt J.
        • Vollmar J.
        • Greten H.
        Wirkung von Bezafibrat auf die Lipoprotein-lipasenaktivität and die Leber-Triglyceridhydrolase bei gesunden Versuchspersonen.
        in: Greten H. Lang P.D. Schettler G. Lipoproteine and Herzinfarkt. Verlag G. Witzstrock, Baden-Baden, Köln, New York1979: 185
        • Eisenberg S.
        Very-low-density lipoprotein metabolism.
        Progr. Biochem. Pharmacol. 1979; 15: 139
        • Ganesan D.
        • Bass H.B.
        • McConathy W.J.
        • Alaupovic P.
        Is decreased activity of C-II activated lipoprotein lipase in type III hyperlipoproteinemia (broad-β-disease) a cause or an effect of increased apolipoprotein E levels?.
        Metabolism. 1976; 35: 1189
        • Breckenridge W.C.
        • Little J.A.
        • Steiner G.
        • Chow A.
        • Poapst M.
        Hypertriglyceridemia associated with deficiency of apolipoprotein C-II.
        N. Engl. J. Med. 1978; 298: 1265
        • La Rosa J.C.
        • Levy R.I.
        • Herbert P.
        • Lux S.E.
        • Fredrickson D.S.
        A specific apoprotein activator for lipoprotein lipase.
        Biochem. Biophys. Res. Comm. 1972; 41: 57
        • Brown W.V.
        • Baginsky M.L.
        Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoproteins.
        Biochem. Biophys. Res. Comm. 1972; 46: 375
        • Innerarity T.L.
        • Mahley R.W.
        Enhanced binding by cultured human fibroblasts of apo- E containing lipoproteins as compared with low-density lipoproteins.
        Biochemistry. 1978; 17: 1440
        • Kashyap M.L.
        • Srivastava L.S.
        • Chen C.Y.
        • Perisutti G.
        • Campbell M.
        • Lutmer R.F.
        • Glueck C.J.
        Radioimmunoassay of human apolipoprotein C II.
        J. Clin. Invest. 1977; 60: 171
        • Carlson L.A.
        • Ballantyne D.
        Changing relative content of apolipoproteins C-II, and C-III of very low density lipoproteins in hypertriglyceridemia.
        Atherosclerosis. 1976; 23: 563
        • Catapano A.L.
        The distribution of apo C-II and apo C-III in very low density lipoproteins of normal and type IV subjects.
        Atherosclerosis. 1980; 35: 419
        • Drosner M.
        • Weisweiler P.
        • Schwandt P.
        Changes of the VLDL-apolipoproteins C in primary type IV-hyperlipoproteinaemia by bezafibrate.
        J. Clin. Chem. Clin. Biochem. 1980; 18 (Abstract): 5.18
        • Beaumont J.-L.
        • Carlson L.A.
        • Cooper G.R.
        • Fejfar Z.
        • Fredrickson D.S.
        • Strasser T.
        Classification of hyperlipidemias and hyperlipoproteinemias.
        Bull. Wld Hlth Org. 1970; 43: 891
        • Schwandt P.
        • Weisweiler P.
        The effect of D-thyroxine on lipoprotein lipids and apolipoproteins in primary type IIa hyperlipoproteinemia.
        Atherosclerosis. 1980; 35: 301
        • Kane J.P.
        • Sata T.
        • Hamilton R.L.
        • Havel R.J.
        Apoprotein composition of very low density lipoproteins of human serum.
        J. Clin. Invest. 1975; 56: 1622
        • Naruszwicz M.
        • Szostak W.B.
        • Cybulska B.
        • Kotlowska M.
        • Chotlowska E.
        The influence of clofibrate on lipid and protein components of very low-density lipoproteins in type IV-hyperlipoproteinemia.
        Atherosclerosis. 1980; 35: 383
        • Schonfeld G.
        • Weidman S.W.
        • Witztum J.L.
        • Bowen R.M.
        Alterations in levels and interrelations of plasma apolipoproteins induced by diet.
        Metabolism. 1976; 25: 261
        • Pagnan A.
        • Casara D.
        • Zanetti G.
        • Guarini P.
        • Graggion M.
        Serum lipids, “double pre-beta lipoproteinemia”, and distribution of the apo-very-low-density (VLDL) lipoprotein peptides in hypothyroid patients before and after substitution therapy.
        Metabolism. 1980; 29: 1026

      Article info

      Publication history

      Accepted: October 13, 1981
      Received: July 24, 1981

      Identification

      DOI: https://doi.org/10.1016/0021-9150(82)90154-X

      Copyright

      © 1982 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX